Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

Olaparib

The articles shown below are all about the Olaparib, through these related articles, you can get relevant information, notes in use, or latest trends about the Olaparib. We hope these news will give you the help you need. And if these Olaparib articles can't solve your needs, you can contact us for relevant information.
  • Drug Briefing: Olaparib

    Drug Briefing: Olaparib

    2025-03-10

    Query Drug：OlaparibQuery Time：2025-03-10 13:13:19*** Disclaimer *** The information provided here is sourced from resources such as Drugs.com, the Orange Book, etc., and is auto-generated by the Unibest Digital Center. The content is intended exclusively for pharmaceutical professionals. Read More
  • New Approval of Olaparib Indication

    New Approval of Olaparib Indication

    2025-03-10

    New Approval of Olaparib IndicationOn January 2nd, AstraZeneca and Merck jointly announced that their PARP inhibitor Lynparza® (Generic name: olaparib) has received approval for a new indication in China. Read More
  • Drug Patent & Exclusivity Expiration Report - Week of March 10 2025

    Drug Patent & Exclusivity Expiration Report - Week of March 10 2025

    2025-03-10

    This week, there are 16 drugs in the patent and exclusivity list. They are: - Yupelri by Mylan Ireland Ltd, containing active ingredient Revefenacin - Xiidra by Bausch and Lomb Inc, containing active ingredient Lifitegrast - Ogsiveo by Springworks Therapeutics Inc, containing active ingredient Nirogacestat Hydrobromide - Koselugo by AstraZeneca Pharmaceuticals LP, containing active ingredient Selumetinib Sulfate - Mektovi by Array Biopharma Inc, containing active ingredient Binimetinib - Viberzi by AbbVie Inc, containing active ingredient Eluxadoline - Lynparza by AstraZeneca Pharmaceuticals LP, containing active ingredient Olaparib Read More